SEC Comment Letter for CYTOKINETICS INC (CYTK) (CIK 0001061983) (CYTK) — Jan 26, 2009
CYTOKINETICS INC (CYTK) (CIK 0001061983)
Date: Jan. 26, 2009 · CIK: 0001061983 · Accession: 0000000000-09-003826
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-50633
Letter
Mail Stop 6010 January 26, 2009 Robert I. Blum President and Chief Executive Officer Cytokinetics, Incorporated 280 East Grand Avenue South San Francisco, California 94080
Re: Cytokinetics, Incorporated Form 10-K Filed March 12, 2008 Response to Comment Letter filed January 16, 2009 File No. 000-50633
Dear Mr. Blum: We have reviewed your filing and have the following comments. Where indicated, we think you should re vise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as deta iled as necessary in your explanation. In some of our comments, we may ask you to provi de us with information so we may better understand your disclosure. After reviewing th is information, we may raise additional comments. Please understand that the purpose of our re view process is to assist you in your compliance with the applicable disclosure requirements and to enhance the overall disclosure in your filing. We look forward to working with you in these respects. We welcome any questions you may have about our comments or any other aspect of our review. Feel free to call us at the telephone numbers listed at the end of this letter. Schedule 14A
Executive Compensation, page 23
1. We note your response to our original comment contains some individual and corporate goals and their relation to elemen ts of compensation. However, certain phrases like, “such as” and “for example” i ndicate that the goals listed here are not a comprehensive list of those used in determining executive compensation. Please revise your disclosure in this sect ion further to includ e all the individual and corporate goals for the named executive officers that contributed to their
compensation, and clarify how the level of achievement of those goals related to the level of compensation awarded to each named executive officer. Also, please disclose the individual achievement leve l attained by Dr. Wolff as you have for the other two named executive office rs whose compensation was based on individual goals.
* * * Please respond to these comments within 10 business days or tell us when you will provide us with a response. Please contact Mike Rosenthall at 202-551-3674 or me at 202-551-3715 with any other questions. Sincerely,
J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r
Show Raw Text
Mail Stop 6010
January 26, 2009
Robert I. Blum President and Chief Executive Officer Cytokinetics, Incorporated 280 East Grand Avenue South San Francisco, California 94080
Re: Cytokinetics, Incorporated
Form 10-K
Filed March 12, 2008 Response to Comment Letter filed January 16, 2009
File No. 000-50633
Dear Mr. Blum:
We have reviewed your filing and have the following comments. Where
indicated, we think you should re vise your document in response to these comments. If
you disagree, we will consider your explanation as to why our comment is inapplicable or
a revision is unnecessary. Please be as deta iled as necessary in your explanation. In
some of our comments, we may ask you to provi de us with information so we may better
understand your disclosure. After reviewing th is information, we may raise additional
comments. Please understand that the purpose of our re view process is to assist you in your
compliance with the applicable disclosure requirements and to enhance the overall
disclosure in your filing. We look forward to working with you in these respects. We
welcome any questions you may have about our comments or any other aspect of our
review. Feel free to call us at the telephone numbers listed at the end of this letter.
Schedule 14A
Executive Compensation, page 23
1. We note your response to our original comment contains some individual and
corporate goals and their relation to elemen ts of compensation. However, certain
phrases like, “such as” and “for example” i ndicate that the goals listed here are
not a comprehensive list of those used in determining executive compensation.
Please revise your disclosure in this sect ion further to includ e all the individual
and corporate goals for the named executive officers that contributed to their
compensation, and clarify how the level of achievement of those goals related to
the level of compensation awarded to each named executive officer. Also, please
disclose the individual achievement leve l attained by Dr. Wolff as you have for
the other two named executive office rs whose compensation was based on
individual goals.
* * *
Please respond to these comments within 10 business days or tell us when you will provide us with a response. Please contact Mike Rosenthall at 202-551-3674 or me at 202-551-3715 with any
other questions.
Sincerely,
J e f f r e y P . R i e d l e r A s s i s t a n t D i r e c t o r